Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Norchlorcyclizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.62 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.54 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.54 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.68 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.64 |
| ▸ | TACR3 | P29371 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.56 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.54 |
| ▸ | CACNB1 | Q02641 | 3/20 | 0.54 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.54 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norchlorcyclizine SCHEMBL587843 | 1.00 | CYP2D6 (0.68) | CYP2D6CYP19A1OPRD1MEN1KMT2A | |
| Norchlorcyclizine SCHEMBL588832 | 1.00 | CYP2D6 (0.68) | CYP2D6CYP19A1OPRD1MEN1KMT2A | |
| Norchlorcyclizine SCHEMBL3602733 | 1.00 | CYP2D6 (0.68) | CYP2D6CYP19A1OPRD1MEN1KMT2A | |
| Norchlorcyclizine SCHEMBL588655 | 0.89 | CYP2D6 (0.86) | CYP2D6CYP19A1OPRD1MEN1KMT2A | |
| Norchlorcyclizine SCHEMBL467086 | 0.89 | CYP2D6 (0.86) | CYP2D6CYP19A1OPRD1MEN1KMT2A | |
| Norchlorcyclizine SCHEMBL6556514 | 0.89 | CYP2D6 (0.86) | CYP2D6CYP19A1OPRD1MEN1KMT2A | |
| Norchlorcyclizine SCHEMBL2426579 | 0.88 | CYP2D6 (0.69) | CYP2D6CYP19A1OPRD1MEN1KMT2A | |
| Norchlorcyclizine SCHEMBL588155 | 0.87 | CYP2D6 (0.83) | CYP2D6CYP19A1OPRD1MEN1KMT2A | |
| Norchlorcyclizine SCHEMBL4649874 | 0.87 | CYP2D6 (0.83) | CYP2D6CYP19A1OPRD1MEN1KMT2A | |
| Norchlorcyclizine SCHEMBL7139140 | 0.86 | CYP2D6 (0.81) | CYP2D6CYP19A1OPRD1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963296-B1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKOEDOE RESZVENYTARSASAG (HU) | 2012-02-15 | — | — | EP | disclosed |
| US-7851627-B2 | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-12-14 | — | — | US | disclosed |
| US-20090221823-A1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221823-A1 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | HRH4, HRH1, HRH2 | MEN1 4160/4885KMT2A 287/4885CHRM2 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.